2. Search Result
Search Result
Results for "

EEF2K

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

1

Recombinant Proteins

1

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-146324
    PROTAC eEF2K degrader-1

    		PROTACs Apoptosis CaMK Cancer
    PROTAC eEF2K degrader-1 (Compound 11l) is an eEF2K-Targeting PROTAC small molecule that induces apoptosis in MDA-MB-231 cells. PROTAC eEF2K degrader-1 mediates eEF2K degradation .
    PROTAC eEF2K degrader-1
  • HY-100576
    NH125
    2 Publications Verification

    		 CaMK Autophagy Bacterial Fungal Virus Protease Cancer
    NH125 is a potent and selective inhibitor of eukaryotic elongation factor 2 kinase (eEF-2K/CaMKIII), also can induce eEF2 phosphorylation, with an IC50 of 60 nM for eEF-2K [2].
    NH125
  • HY-110096
    A-484954
    5+ Cited Publications

    		 CaMK Autophagy Cancer
    A-484954 is a highly selective eukaryotic elongationfactor-2 kinase(eEF2K) inhibitor, with an IC50 of 280 nM.
    A-484954
  • HY-177720
    eEF2K degrader-2

    		Molecular Glues CaMK Apoptosis Cancer
    eEF2K degrader-2 is a molecular glucose degrading agent that targets the eEF2K protein. eEF2K degrader-2 can significantly inhibit the proliferation, migration, invasion and induce apoptosis of triple negative breast cancer (TNBC) cells. eEF2K degrader-2 has no obvious organ toxicity or pathological damage. eEF2K degrader-2 can be used in the research of cancer such as breast cancer .
    eEF2K degrader-2
  • HY-RS20013
    Eef2k Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Eef2k Mouse Pre-designed siRNA Set A contains three designed siRNAs for Eef2k gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Eef2k Mouse Pre-designed siRNA Set A
    Eef2k Mouse Pre-designed siRNA Set A
  • HY-RS04181
    EEF2K Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    EEF2K Human Pre-designed siRNA Set A contains three designed siRNAs for EEF2K gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    EEF2K Human Pre-designed siRNA Set A
    EEF2K Human Pre-designed siRNA Set A
  • HY-RS26516
    Eef2k Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Eef2k Rat Pre-designed siRNA Set A contains three designed siRNAs for Eef2k gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Eef2k Rat Pre-designed siRNA Set A
    Eef2k Rat Pre-designed siRNA Set A
  • HY-121828
    TX-1123

    		Src CaMK PKA EGFR PKC COX Cancer
    TX-1123 is a potent protein tyrosine kinase (PTK) inhibitor for Src, eEF2-K, and PKA, and EGFR-K/PKC. TX-1123 is a cyclo-oxygenase (COX) inhibitor with IC50 values of 1.16 μM and 15.7 μM for COX2 and COX1, respectively. TX-1123 has low mitochondrial toxicity. TX-1123 can be used in research of cancer [2].
    TX-1123
  • HY-123024
    Cefatrizine

    BL-S-640; SK&F 60771

    		 Apoptosis Bacterial Antibiotic Infection Cancer
    Cefatrizine (BL-S-640) is an orally active and broad-spectrum cephalosporin antibiotic. Cefatrizine is also a eEF2K inhibitor, with anti-proliferative activity in human breast cancer cells, which could induce ER stress, leading to cell death. Cefatrizine can be used in studies of cancer and bacterial infection [2].
    Cefatrizine
  • HY-112393
    TX-1918

    		HIV Src PKA PKC Infection
    TX-1918 is an inhibitor for eukaryotic elongation factor 2 kinase (eEF2-K) and Src kinase with IC50 of 0.44 and 4.4 μM, respectively. TX-1918 exhibits cytotoxicity in cell HepG2 and HCT116, with IC50 of 2.07 and 230 μM, respectively. TX-1918 inhibits the C-terminal domain of HIV-1 CA (CA CTD)(IC50 =3.81 μM), and inhibits the viral replication (IC50 =15.16 μM) [2].
    TX-1918
  • HY-176149
    Fluoxetine-Conjugated Platinum(IV) prodrug-1

    		CaMK MMP AMPK Apoptosis Autophagy Cancer
    Fluoxetine-Conjugated Platinum(IV) prodrug-1 (Compound 8) is an eEF2K inhibitor. Fluoxetine-Conjugated Platinum(IV) prodrug-1 inhibits cancer cell proliferation, induces DNA damage, cell cycle arrest at S phase and apoptosis. Fluoxetine-Conjugated Platinum(IV) prodrug-1 induces ROS accumulation and mitochondrial dysfunction. Fluoxetine-Conjugated Platinum(IV) prodrug-1 inhibits TNBC cell migration and invasion by inhibiting MMP-2 activity. Fluoxetine-Conjugated Platinum(IV) prodrug-1 induces autophagy in TNBC cells by activating AMPK. Fluoxetine-Conjugated Platinum(IV) prodrug-1 has antitumor activity and activates immunosuppression in the 4T1-Luc mouse model. Fluoxetine-Conjugated Platinum(IV) prodrug-1 can be used in triple-negative breast cancer (TNBC) research .
    Fluoxetine-Conjugated Platinum(IV) prodrug-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: